Research in the Chapkin lab focuses on dietary/microbial modulators related to the prevention of cancer and chronic inflammatory diseases. The lab has been continuously funded by the National Institutes of Health (NIH) for the past 35 years.
Most Recent NIH Award: Nutritional and clinical predictors of intestinal maturation and feeding tolerance in the preterm infant
The Chapkin Lab is excited to work with the Single Cell Science Data Core established through the Texas Regional Center of Excellence in Cancer Research – TREC.
March 19, 2024, 2-3pm: Dr. Shreya Raghavan; Medical Research Education Building #2 1403
April 15, 2024, 11-12pm: Dr. Yong Li; Medical Research Education Building #2 1403
*check out the TREC website to find out more information about the upcoming speaker seminars and our annual symposium
- Texas A&M AgriLife researcher receives $4 million grant to study feeding intolerance in preterm infantsNovel noninvasive method allows for precise diagnosis of feeding intolerance severity Texas A&M AgriLife researcher… Read more: Texas A&M AgriLife researcher receives $4 million grant to study feeding intolerance in preterm infants
- Nutritional and clinical predictors of intestinal maturation and feeding tolerance in the preterm infantMajor Goals: Annotate host exfoliated mucosal cell transcriptome, i.e., exfoliome, and fecal bacterial metagenome and… Read more: Nutritional and clinical predictors of intestinal maturation and feeding tolerance in the preterm infant
- Texas A&M University Faculty AffairsCongratulates Dr. Robert Chapkin for ASN Award
- BREAKTHROUGH IN Wnt SIGNALING PUBLISHED!Breakthrough publication! Our recent paper in Nature Communications explains the novel structure-function mechanism by which… Read more: BREAKTHROUGH IN Wnt SIGNALING PUBLISHED!
FOLLOW US ON X (formerly known as Twitter) @ChapkinLab
Congrats to the 2023 Mary Swartz Rose Investigator Awardees, shown here at the @nutritionorg #Nutrition2023 event in Boston yesterday! These awards are given for outstanding #research on the #safety & efficacy of bioactive compounds for human #health. https://t.co/RtGTwMQRrN pic.twitter.com/phLIP6JzyA— CRN (@CRN_Supplements) July 24, 2023